{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "07", "@year": "2021", "@timestamp": "2021-10-07T09:44:48.000048-04:00", "@month": "10"}, "ait:date-sort": {"@day": "08", "@year": "2016", "@month": "08"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "Thailand", "@afid": "117369800", "@country": "tha", "organization": [{"$": "Department of Pharmacy Practice"}, {"$": "Faculty of Pharmaceutical Science"}], "affiliation-id": {"@afid": "117369800", "@dptid": "117370517"}, "@dptid": "117370517"}, "author": [{"ce:given-name": "Wanaporn", "preferred-name": {"ce:given-name": "Wanaporn", "ce:initials": "W.", "ce:surname": "Charoenchokthavee", "ce:indexed-name": "Charoenchokthavee W."}, "@seq": "1", "ce:initials": "W.", "@_fa": "true", "@type": "auth", "ce:surname": "Charoenchokthavee", "@auid": "57189578502", "ce:indexed-name": "Charoenchokthavee W."}, {"ce:given-name": "Duangchit", "preferred-name": {"ce:given-name": "Duangchit", "ce:initials": "D.", "ce:surname": "Panomvana", "ce:indexed-name": "Panomvana D."}, "@seq": "2", "ce:initials": "D.", "@_fa": "true", "@type": "auth", "ce:surname": "Panomvana", "@auid": "6504552026", "ce:indexed-name": "Panomvana D."}, {"ce:given-name": "Nutthada", "preferred-name": {"ce:given-name": "Nutthada", "ce:initials": "N.", "ce:surname": "Areepium", "ce:indexed-name": "Areepium N."}, "@seq": "4", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Areepium", "@auid": "13610558100", "ce:indexed-name": "Areepium N."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Medical Oncology Unit"}, {"$": "Department of Medicine"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "113019942"}, "@dptid": "113019942"}, "author": [{"ce:given-name": "Virote", "preferred-name": {"ce:given-name": "Virote", "ce:initials": "V.", "ce:surname": "Sriuranpong", "ce:indexed-name": "Sriuranpong V."}, "@seq": "3", "ce:initials": "V.", "@_fa": "true", "@type": "auth", "ce:surname": "Sriuranpong", "@auid": "6603599644", "ce:indexed-name": "Sriuranpong V."}]}], "citation-title": "Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment", "abstracts": "\u00a9 2016 Charoenchokthavee et al.Background: Tamoxifen (TAM) is used in breast cancer treatment, but interindividual variabilities in TAM-metabolizing enzymes exist and have been linked to single nucleotide polymorphisms in the respective encoding genes. The different alleles and genotypes of these genes have been presented for Caucasians and Asians. This study aimed to explore the prevalence of the incomplete functional alleles and genotypes of the CYP2D6 and CYP3A5 genes in Thai breast cancer patients undergoing TAM treatment. Patients and methods: In total, 134 Thai breast cancer patients were randomly invited to join the Thai Tamoxifen Project. Their blood samples were collected and extracted for individual DNA. The alleles and genotypes were determined by real-time polymerase chain reaction with TaqMan\u00ae Drug Metabolism Genotyping Assays. Results: The patients were aged from 27.0 years to 82.0 years with a body mass index range from 15.4 to 40.0, with the majority (103/134) in the early stage (stages 0-II) of breast cancer. The median duration of TAM administration was 17.2 months (interquartile range 16.1 months). Most (53%) of the patients were premenopausal with an estrogen receptor (ER) and progesterone receptor (PR) status of ER+/PR+ (71.7%), ER+/PR- (26.9%), ER-/PR+ (0.7%), and ER-/PR- (0.7%). The allele frequencies of CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*10, CYP3A5*1, and CYP3A5*3 were 72.9%, 3.2%, 1.1%, 22.8%, 37.3%, and 62.7%, respectively, while the genotype frequencies of CYP2D6*1/*1, CYP2D6*1/*2, CYP2D6*2/*2, CYP2D6*4/*4, CYP2D6*1/*10, CYP2D6*2/*10, CYP2D6*4/*10, CYP2D6*10/*10, CYP3A5*1/*1, CYP3A5*1/*3, and CYP3A5*3/*3 were 9.7%, 2.2%, 3.7%, 1.5%, 15.7%, 9.7%, 3.7%, 53.7%, 13.4%, 47.8%, and 38.8%, respectively. Conclusion: The majority (97.8%) of Thai breast cancer patients undergoing TAM treatment carry at least one incomplete functional allele, including 20.9% of the patients who carry only incomplete functional alleles for both the CYP2D6 and CYP3A5 genes. This research indicates the high prevalence of these defective alleles that are involved in TAM-metabolic pathways that might further affect TAM treatment.", "correspondence": {"affiliation": {"country": "Thailand", "address-part": "254 Phayathai Road, Pathumwan", "postal-code": "10330", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Pharmacy Practice"}, {"$": "Faculty of Pharmaceutical Science"}, {"$": "Chulalongkorn University"}]}, "person": {"ce:given-name": "Nutthada", "ce:initials": "N.", "ce:surname": "Areepium", "ce:indexed-name": "Areepium N."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "Antihormone", "@xml:lang": "eng"}, {"$": "CYP450", "@xml:lang": "eng"}, {"$": "Oncology", "@xml:lang": "eng"}, {"$": "Pharmacogenetics", "@xml:lang": "eng"}, {"$": "Pharmacogenomics", "@xml:lang": "eng"}, {"$": "SNPs", "@xml:lang": "eng"}]}, "citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"sourcetitle-abbrev": "Breast Cancer: Target Ther.", "website": {"ce:e-address": {"$": "https://www.dovepress.com/getfile.php?fileID=31781", "@type": "email"}}, "@country": "gbr", "translated-sourcetitle": {"$": "Breast Cancer: Targets and Therapy", "@xml:lang": "eng"}, "issn": {"$": "11791314", "@type": "electronic"}, "volisspag": {"voliss": {"@volume": "8"}, "pagerange": {"@first": "149", "@last": "155"}}, "@type": "j", "publicationyear": {"@first": "2016"}, "publisher": {"affiliation": {"address-part": "PO Box 300-008, Albany", "@country": "nzl", "city": "Auckland"}, "publishername": "Dove Medical Press Ltd."}, "sourcetitle": "Breast Cancer: Targets and Therapy", "@srcid": "19700175783", "publicationdate": {"month": "08", "year": "2016", "date-text": {"@xfab-added": "true", "$": "8 August 2016"}, "day": "08"}}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "EMCLASS", "classification": [{"classification-code": "16", "classification-description": "Cancer"}, {"classification-code": "22", "classification-description": "Human Genetics"}, {"classification-code": "29", "classification-description": "Clinical and Experimental Biochemistry"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}]}, {"@type": "ASJC", "classification": "2730"}, {"@type": "SUBJABBR", "classification": "MEDI"}]}, "chemicalgroup": {"chemicals": {"@source": "esbd", "chemical": [{"cas-registry-number": [{"$": "9000-86-6"}, {"$": "9014-30-6"}], "enzyme-commission-number": "EC 2.6.1.2", "chemical-name": "alanine aminotransferase"}, {"cas-registry-number": "9000-97-9", "enzyme-commission-number": "EC 2.6.1.1", "chemical-name": "aspartate aminotransferase"}, {"cas-registry-number": "336874-97-6", "chemical-name": "cytochrome P450 3A5"}, {"cas-registry-number": "10540-29-1", "chemical-name": "tamoxifen"}]}}}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "EMBASE"}, {"$": "REAXYSCAR"}, {"$": "RMC"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "27", "@year": "2016", "@timestamp": "BST 11:38:01", "@month": "09"}}, "itemidlist": {"itemid": [{"$": "612204624", "@idtype": "PUI"}, {"$": "655369663", "@idtype": "CAR-ID"}, {"$": "20160674748", "@idtype": "EMBASE"}, {"$": "20161950365", "@idtype": "REAXYSCAR"}, {"$": "2016275418", "@idtype": "RMC"}, {"$": "84987910762", "@idtype": "SCP"}, {"$": "84987910762", "@idtype": "SGR"}], "ce:doi": "10.2147/BCTT.S105563"}}, "tail": {"bibliography": {"@refcount": "26", "reference": [{"ref-fulltext": "Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics. 2013;23(11):643-647.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "PharmGKB summary: Tamoxifen pathway, pharmacokinetics"}, "refd-itemidlist": {"itemid": {"$": "84886582469", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "23", "@issue": "11"}, "pagerange": {"@first": "643", "@last": "647"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.J.", "@_fa": "true", "ce:surname": "Klein", "ce:indexed-name": "Klein D.J."}, {"@seq": "2", "ce:initials": "C.F.", "@_fa": "true", "ce:surname": "Thorn", "ce:indexed-name": "Thorn C.F."}, {"@seq": "3", "ce:initials": "Z.", "@_fa": "true", "ce:surname": "Desta", "ce:indexed-name": "Desta Z."}, {"@seq": "4", "ce:initials": "D.A.", "@_fa": "true", "ce:surname": "Flockhart", "ce:indexed-name": "Flockhart D.A."}, {"@seq": "5", "ce:initials": "R.B.", "@_fa": "true", "ce:surname": "Altman", "ce:indexed-name": "Altman R.B."}, {"@seq": "6", "ce:initials": "T.E.", "@_fa": "true", "ce:surname": "Klein", "ce:indexed-name": "Klein T.E."}]}, "ref-sourcetitle": "Pharmacogenet Genomics"}}, {"ref-fulltext": "Saladores PH, Precht JC, Schroth W, Brauch H, Schwab M. Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. Expert Rev Mol Diagn. 2013;13(4):349-365.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer"}, "refd-itemidlist": {"itemid": {"$": "84877304851", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "13", "@issue": "4"}, "pagerange": {"@first": "349", "@last": "365"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.H.", "@_fa": "true", "ce:surname": "Saladores", "ce:indexed-name": "Saladores P.H."}, {"@seq": "2", "ce:initials": "J.C.", "@_fa": "true", "ce:surname": "Precht", "ce:indexed-name": "Precht J.C."}, {"@seq": "3", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Schroth", "ce:indexed-name": "Schroth W."}, {"@seq": "4", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Brauch", "ce:indexed-name": "Brauch H."}, {"@seq": "5", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Schwab", "ce:indexed-name": "Schwab M."}]}, "ref-sourcetitle": "Expert Rev Mol Diagn"}}, {"ref-fulltext": "Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients"}, "refd-itemidlist": {"itemid": {"$": "84859054082", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "104", "@issue": "6"}, "pagerange": {"@first": "452", "@last": "460"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.M.", "@_fa": "true", "ce:surname": "Rae", "ce:indexed-name": "Rae J.M."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Drury", "ce:indexed-name": "Drury S."}, {"@seq": "3", "ce:initials": "D.F.", "@_fa": "true", "ce:surname": "Hayes", "ce:indexed-name": "Hayes D.F."}], "et-al": null}, "ref-sourcetitle": "J Natl Cancer Inst"}}, {"ref-fulltext": "Karle J, Bolbrinker J, Vogl S, et al. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Res Treat. 2013;139(2):553-560.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer"}, "refd-itemidlist": {"itemid": {"$": "84878759686", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "139", "@issue": "2"}, "pagerange": {"@first": "553", "@last": "560"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Karle", "ce:indexed-name": "Karle J."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Bolbrinker", "ce:indexed-name": "Bolbrinker J."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Vogl", "ce:indexed-name": "Vogl S."}], "et-al": null}, "ref-sourcetitle": "Breast Cancer Res Treat"}}, {"ref-fulltext": "Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrineresponsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441-451.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrineresponsive breast cancer: The breast international group 1-98 trial"}, "refd-itemidlist": {"itemid": {"$": "84859093970", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "104", "@issue": "6"}, "pagerange": {"@first": "441", "@last": "451"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.M.", "@_fa": "true", "ce:surname": "Regan", "ce:indexed-name": "Regan M.M."}, {"@seq": "2", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Leyland-Jones", "ce:indexed-name": "Leyland-Jones B."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Bouzyk", "ce:indexed-name": "Bouzyk M."}], "et-al": null}, "ref-sourcetitle": "J Natl Cancer Inst"}}, {"ref-fulltext": "Westbrook K, Stearns V. Pharmacogenomics of breast cancer therapy: an update. Pharmacol Ther. 2013;139(1):1-11.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Pharmacogenomics of breast cancer therapy: An update"}, "refd-itemidlist": {"itemid": {"$": "84877927925", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "139", "@issue": "1"}, "pagerange": {"@first": "1", "@last": "11"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Westbrook", "ce:indexed-name": "Westbrook K."}, {"@seq": "2", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Stearns", "ce:indexed-name": "Stearns V."}]}, "ref-sourcetitle": "Pharmacol Ther"}}, {"ref-fulltext": "Binkhorst L, Mathijssen RHJ, Ghobadi Moghaddam-Helmantel IM, et al. Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2011;56(5):1016-1023.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry"}, "refd-itemidlist": {"itemid": {"$": "80052791490", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "56", "@issue": "5"}, "pagerange": {"@first": "1016", "@last": "1023"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Binkhorst", "ce:indexed-name": "Binkhorst L."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Mathijssen", "ce:indexed-name": "Mathijssen R."}, {"@seq": "3", "ce:initials": "I.M.", "@_fa": "true", "ce:surname": "Ghobadi Moghaddam-Helmantel", "ce:indexed-name": "Ghobadi Moghaddam-Helmantel I.M."}], "et-al": null}, "ref-sourcetitle": "J Pharm Biomed Anal"}}, {"ref-fulltext": "Chamnanphon M, Pechatanan K, Sirachainan E, et al. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmacogenomics Pers Med. 2013;6(1):37-48.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen"}, "refd-itemidlist": {"itemid": {"$": "84878302608", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6", "@issue": "1"}, "pagerange": {"@first": "37", "@last": "48"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Chamnanphon", "ce:indexed-name": "Chamnanphon M."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Pechatanan", "ce:indexed-name": "Pechatanan K."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Sirachainan", "ce:indexed-name": "Sirachainan E."}], "et-al": null}, "ref-sourcetitle": "Pharmacogenomics Pers Med"}}, {"ref-fulltext": "Sensorn I, Sirachainan E, Chamnanphon M, et al. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmacogenomics Pers Med. 2013;6(1):93-98.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen"}, "refd-itemidlist": {"itemid": {"$": "84883228374", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "6", "@issue": "1"}, "pagerange": {"@first": "93", "@last": "98"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Sensorn", "ce:indexed-name": "Sensorn I."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Sirachainan", "ce:indexed-name": "Sirachainan E."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Chamnanphon", "ce:indexed-name": "Chamnanphon M."}], "et-al": null}, "ref-sourcetitle": "Pharmacogenomics Pers Med"}}, {"ref-fulltext": "Lum DWK, Perel P, Hingorani AD, Holmes MV. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One. 2013;8(10):e76648.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "CYP2D6 genotype and tamoxifen response for breast cancer: A systematic review and meta-analysis"}, "refd-itemidlist": {"itemid": {"$": "84884836449", "@idtype": "SGR"}}, "ref-volisspag": {"pages": "e76648", "voliss": {"@volume": "8", "@issue": "10"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Lum", "ce:indexed-name": "Lum D."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Perel", "ce:indexed-name": "Perel P."}, {"@seq": "3", "ce:initials": "A.D.", "@_fa": "true", "ce:surname": "Hingorani", "ce:indexed-name": "Hingorani A.D."}, {"@seq": "4", "ce:initials": "M.V.", "@_fa": "true", "ce:surname": "Holmes", "ce:indexed-name": "Holmes M.V."}]}, "ref-sourcetitle": "Plos One"}}, {"ref-fulltext": "Province MA, Goetz MP, Brauch H, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther. 2014;95(2):216-227.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "CYP2D6 genotype and adjuvant tamoxifen: Meta-analysis of heterogeneous study populations"}, "refd-itemidlist": {"itemid": {"$": "84893732936", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "95", "@issue": "2"}, "pagerange": {"@first": "216", "@last": "227"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.A.", "@_fa": "true", "ce:surname": "Province", "ce:indexed-name": "Province M.A."}, {"@seq": "2", "ce:initials": "M.P.", "@_fa": "true", "ce:surname": "Goetz", "ce:indexed-name": "Goetz M.P."}, {"@seq": "3", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Brauch", "ce:indexed-name": "Brauch H."}], "et-al": null}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89(5):718-725.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes"}, "refd-itemidlist": {"itemid": {"$": "79955485361", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "89", "@issue": "5"}, "pagerange": {"@first": "718", "@last": "725"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Madlensky", "ce:indexed-name": "Madlensky L."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Natarajan", "ce:indexed-name": "Natarajan L."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Tchu", "ce:indexed-name": "Tchu S."}], "et-al": null}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Gjerde J, Geisler J, Lundgren S, et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 2010;10(1):313.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer"}, "refd-itemidlist": {"itemid": {"$": "77953679656", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "10", "@issue": "1"}, "pagerange": {"@first": "313"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Gjerde", "ce:indexed-name": "Gjerde J."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Geisler", "ce:indexed-name": "Geisler J."}, {"@seq": "3", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Lundgren", "ce:indexed-name": "Lundgren S."}], "et-al": null}, "ref-sourcetitle": "BMC Cancer"}}, {"ref-fulltext": "Lim JS, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71(5):737-750.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients"}, "refd-itemidlist": {"itemid": {"$": "79953848236", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "71", "@issue": "5"}, "pagerange": {"@first": "737", "@last": "750"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.S.", "@_fa": "true", "ce:surname": "Lim", "ce:indexed-name": "Lim J.S."}, {"@seq": "2", "ce:initials": "X.A.", "@_fa": "true", "ce:surname": "Chen", "ce:indexed-name": "Chen X.A."}, {"@seq": "3", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Singh", "ce:indexed-name": "Singh O."}], "et-al": null}, "ref-sourcetitle": "Br J Clin Pharmacol"}}, {"ref-fulltext": "Teh LK, Mohamed NI, Salleh MZ, et al. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J. 2012;14(1):52-59.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1"}, "refd-itemidlist": {"itemid": {"$": "84857627005", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "14", "@issue": "1"}, "pagerange": {"@first": "52", "@last": "59"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.K.", "@_fa": "true", "ce:surname": "Teh", "ce:indexed-name": "Teh L.K."}, {"@seq": "2", "ce:initials": "N.I.", "@_fa": "true", "ce:surname": "Mohamed", "ce:indexed-name": "Mohamed N.I."}, {"@seq": "3", "ce:initials": "M.Z.", "@_fa": "true", "ce:surname": "Salleh", "ce:indexed-name": "Salleh M.Z."}], "et-al": null}, "ref-sourcetitle": "AAPS J"}}, {"ref-fulltext": "Areepium N, Panomvana D, Rungwanonchai P, Sathaporn S, Voravud N. Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients. Breast Cancer (Dove Med Press). 2013;5:73-78.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients"}, "refd-itemidlist": {"itemid": {"$": "84924907383", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5"}, "pagerange": {"@first": "73", "@last": "78"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Areepium", "ce:indexed-name": "Areepium N."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Panomvana", "ce:indexed-name": "Panomvana D."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Rungwanonchai", "ce:indexed-name": "Rungwanonchai P."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Sathaporn", "ce:indexed-name": "Sathaporn S."}, {"@seq": "5", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Voravud", "ce:indexed-name": "Voravud N."}]}, "ref-sourcetitle": "Breast Cancer (Dove Med Press)"}}, {"ref-fulltext": "Zafra-Ceres M, de Haro T, Farez-Vidal E, et al. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer. Int J Med Sci. 2013;10(7):932-937.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer"}, "refd-itemidlist": {"itemid": {"$": "84878958399", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "10", "@issue": "7"}, "pagerange": {"@first": "932", "@last": "937"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Zafra-Ceres", "ce:indexed-name": "Zafra-Ceres M."}, {"@seq": "2", "ce:initials": "T.", "@_fa": "true", "ce:surname": "De Haro", "ce:indexed-name": "De Haro T."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Farez-Vidal", "ce:indexed-name": "Farez-Vidal E."}], "et-al": null}, "ref-sourcetitle": "Int J Med Sci"}}, {"ref-fulltext": "M\u00fcrdter TE, Schroth W, Bacchus-Gerybadze L, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):1-10.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma"}, "refd-itemidlist": {"itemid": {"$": "79955480679", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "89", "@issue": "5"}, "pagerange": {"@first": "1", "@last": "10"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.E.", "@_fa": "true", "ce:surname": "M\u00fcrdter", "ce:indexed-name": "Murdter T.E."}, {"@seq": "2", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Schroth", "ce:indexed-name": "Schroth W."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Bacchus-Gerybadze", "ce:indexed-name": "Bacchus-Gerybadze L."}], "et-al": null}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Barginear MF, Jaremko M, Peter I, et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011;90(4):605-611.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: Effect on active metabolite isomers and the antiestrogenic activity score"}, "refd-itemidlist": {"itemid": {"$": "80052971654", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "90", "@issue": "4"}, "pagerange": {"@first": "605", "@last": "611"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.F.", "@_fa": "true", "ce:surname": "Barginear", "ce:indexed-name": "Barginear M.F."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Jaremko", "ce:indexed-name": "Jaremko M."}, {"@seq": "3", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Peter", "ce:indexed-name": "Peter I."}], "et-al": null}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Ratain MJ, Nakamura Y, Cox NJ. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther. 2013;94(2):185-187.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "CYP2D6 genotype and tamoxifen activity: Understanding interstudy variability in methodological quality"}, "refd-itemidlist": {"itemid": {"$": "84880758064", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "94", "@issue": "2"}, "pagerange": {"@first": "185", "@last": "187"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.J.", "@_fa": "true", "ce:surname": "Ratain", "ce:indexed-name": "Ratain M.J."}, {"@seq": "2", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Nakamura", "ce:indexed-name": "Nakamura Y."}, {"@seq": "3", "ce:initials": "N.J.", "@_fa": "true", "ce:surname": "Cox", "ce:indexed-name": "Cox N.J."}]}, "ref-sourcetitle": "Clin Pharmacol Ther"}}, {"ref-fulltext": "Hertz DL, McLeod HL, Irvin WJ Jr. Tamoxifen and CYP2D6: a contradiction of data. Oncologist. 2012;17(5):620-630.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Tamoxifen and CYP2D6: A contradiction of data"}, "refd-itemidlist": {"itemid": {"$": "84859999600", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "17", "@issue": "5"}, "pagerange": {"@first": "620", "@last": "630"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.L.", "@_fa": "true", "ce:surname": "Hertz", "ce:indexed-name": "Hertz D.L."}, {"@seq": "2", "ce:initials": "H.L.", "@_fa": "true", "ce:surname": "McLeod", "ce:indexed-name": "McLeod H.L."}, {"@seq": "3", "ce:initials": "W.J.", "@_fa": "true", "ce:surname": "Irvin", "ce:suffix": "Jr.", "ce:indexed-name": "Irvin W.J."}]}, "ref-sourcetitle": "Oncologist"}}, {"ref-fulltext": "Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-141.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation"}, "refd-itemidlist": {"itemid": {"$": "84875211310", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "138", "@issue": "1"}, "pagerange": {"@first": "103", "@last": "141"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "U.M.", "@_fa": "true", "ce:surname": "Zanger", "ce:indexed-name": "Zanger U.M."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Schwab", "ce:indexed-name": "Schwab M."}]}, "ref-sourcetitle": "Pharmacol Ther"}}, {"ref-fulltext": "Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet. 2012;27(1):55-67.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance"}, "refd-itemidlist": {"itemid": {"$": "84857705331", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "27", "@issue": "1"}, "pagerange": {"@first": "55", "@last": "67"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.K.", "@_fa": "true", "ce:surname": "Teh", "ce:indexed-name": "Teh L.K."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Bertilsson", "ce:indexed-name": "Bertilsson L."}]}, "ref-sourcetitle": "Drug Metab Pharmacokinet"}}, {"ref-fulltext": "Fern\u00e1ndez-Santander A, Gaibar M, Novillo A, et al. Relationship between genotypes SULT1A2 and CYP2D6 and tamoxifen metabolism in breast cancer patients. PLoS One. 2013;8(7):e70183.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Relationship between genotypes SULT1A2 and CYP2D6 and tamoxifen metabolism in breast cancer patients"}, "refd-itemidlist": {"itemid": {"$": "84880782733", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "8", "@issue": "7"}, "pagerange": {"@first": "e70183"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Fern\u00e1ndez-Santander", "ce:indexed-name": "Fernandez-Santander A."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Gaibar", "ce:indexed-name": "Gaibar M."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Novillo", "ce:indexed-name": "Novillo A."}], "et-al": null}, "ref-sourcetitle": "Plos One"}}, {"ref-fulltext": "Lyon E, Gastier Foster J, Palomaki GE, et al. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet Med. 2012; 14(12):990-1000.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy"}, "refd-itemidlist": {"itemid": {"$": "84870674888", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "14", "@issue": "12"}, "pagerange": {"@first": "990", "@last": "1000"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Lyon", "ce:indexed-name": "Lyon E."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Gastier Foster", "ce:indexed-name": "Gastier Foster J."}, {"@seq": "3", "ce:initials": "G.E.", "@_fa": "true", "ce:surname": "Palomaki", "ce:indexed-name": "Palomaki G.E."}], "et-al": null}, "ref-sourcetitle": "Genet Med"}}, {"ref-fulltext": "Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013;25(5):534-553.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Complexities of CYP2D6 gene analysis and interpretation"}, "refd-itemidlist": {"itemid": {"$": "84886690638", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "25", "@issue": "5"}, "pagerange": {"@first": "534", "@last": "553"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Gaedigk", "ce:indexed-name": "Gaedigk A."}]}, "ref-sourcetitle": "Int Rev Psychiatry"}}]}}}}, "affiliation": [{"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, {"affiliation-city": "Hat Yai, Songkhla", "@id": "117369800", "affilname": "Faculty of Pharmaceutical Sciences", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117369800", "affiliation-country": "Thailand"}], "coredata": {"srctype": "j", "eid": "2-s2.0-84987910762", "dc:description": "Background: Tamoxifen (TAM) is used in breast cancer treatment, but interindividual variabilities in TAM-metabolizing enzymes exist and have been linked to single nucleotide polymorphisms in the respective encoding genes. The different alleles and genotypes of these genes have been presented for Caucasians and Asians. This study aimed to explore the prevalence of the incomplete functional alleles and genotypes of the CYP2D6 and CYP3A5 genes in Thai breast cancer patients undergoing TAM treatment. Patients and methods: In total, 134 Thai breast cancer patients were randomly invited to join the Thai Tamoxifen Project. Their blood samples were collected and extracted for individual DNA. The alleles and genotypes were determined by real-time polymerase chain reaction with TaqMan\u00ae Drug Metabolism Genotyping Assays. Results: The patients were aged from 27.0 years to 82.0 years with a body mass index range from 15.4 to 40.0, with the majority (103/134) in the early stage (stages 0-II) of breast cancer. The median duration of TAM administration was 17.2 months (interquartile range 16.1 months). Most (53%) of the patients were premenopausal with an estrogen receptor (ER) and progesterone receptor (PR) status of ER+/PR+ (71.7%), ER+/PR- (26.9%), ER-/PR+ (0.7%), and ER-/PR- (0.7%). The allele frequencies of CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*10, CYP3A5*1, and CYP3A5*3 were 72.9%, 3.2%, 1.1%, 22.8%, 37.3%, and 62.7%, respectively, while the genotype frequencies of CYP2D6*1/*1, CYP2D6*1/*2, CYP2D6*2/*2, CYP2D6*4/*4, CYP2D6*1/*10, CYP2D6*2/*10, CYP2D6*4/*10, CYP2D6*10/*10, CYP3A5*1/*1, CYP3A5*1/*3, and CYP3A5*3/*3 were 9.7%, 2.2%, 3.7%, 1.5%, 15.7%, 9.7%, 3.7%, 53.7%, 13.4%, 47.8%, and 38.8%, respectively. Conclusion: The majority (97.8%) of Thai breast cancer patients undergoing TAM treatment carry at least one incomplete functional allele, including 20.9% of the patients who carry only incomplete functional alleles for both the CYP2D6 and CYP3A5 genes. This research indicates the high prevalence of these defective alleles that are involved in TAM-metabolic pathways that might further affect TAM treatment.", "prism:coverDate": "2016-08-08", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/84987910762", "dc:creator": {"author": [{"ce:given-name": "Wanaporn", "preferred-name": {"ce:given-name": "Wanaporn", "ce:initials": "W.", "ce:surname": "Charoenchokthavee", "ce:indexed-name": "Charoenchokthavee W."}, "@seq": "1", "ce:initials": "W.", "@_fa": "true", "affiliation": {"@id": "117369800", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117369800"}, "ce:surname": "Charoenchokthavee", "@auid": "57189578502", "author-url": "https://api.elsevier.com/content/author/author_id/57189578502", "ce:indexed-name": "Charoenchokthavee W."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/84987910762"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84987910762&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84987910762&origin=inward"}], "source-id": "19700175783", "citedby-count": "8", "prism:volume": "8", "subtype": "ar", "dc:title": "Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment", "openaccess": "1", "prism:issn": "11791314", "publishercopyright": "\u00a9 2016 Charoenchokthavee et al.", "subtypeDescription": "Article", "prism:publicationName": "Breast Cancer: Targets and Therapy", "prism:pageRange": "149-155", "prism:endingPage": "155", "openaccessFlag": "true", "prism:doi": "10.2147/BCTT.S105563", "prism:startingPage": "149", "dc:identifier": "SCOPUS_ID:84987910762", "dc:publisher": "Dove Medical Press Ltd.PO Box 300-008, AlbanyAuckland"}, "idxterms": null, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "Antihormone"}, {"@_fa": "true", "$": "CYP450"}, {"@_fa": "true", "$": "Oncology"}, {"@_fa": "true", "$": "Pharmacogenetics"}, {"@_fa": "true", "$": "Pharmacogenomics"}, {"@_fa": "true", "$": "SNPs"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Oncology", "@code": "2730", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Wanaporn", "preferred-name": {"ce:given-name": "Wanaporn", "ce:initials": "W.", "ce:surname": "Charoenchokthavee", "ce:indexed-name": "Charoenchokthavee W."}, "@seq": "1", "ce:initials": "W.", "@_fa": "true", "affiliation": {"@id": "117369800", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117369800"}, "ce:surname": "Charoenchokthavee", "@auid": "57189578502", "author-url": "https://api.elsevier.com/content/author/author_id/57189578502", "ce:indexed-name": "Charoenchokthavee W."}, {"ce:given-name": "Duangchit", "preferred-name": {"ce:given-name": "Duangchit", "ce:initials": "D.", "ce:surname": "Panomvana", "ce:indexed-name": "Panomvana D."}, "@seq": "2", "ce:initials": "D.", "@_fa": "true", "affiliation": {"@id": "117369800", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117369800"}, "ce:surname": "Panomvana", "@auid": "6504552026", "author-url": "https://api.elsevier.com/content/author/author_id/6504552026", "ce:indexed-name": "Panomvana D."}, {"ce:given-name": "Virote", "preferred-name": {"ce:given-name": "Virote", "ce:initials": "V.", "ce:surname": "Sriuranpong", "ce:indexed-name": "Sriuranpong V."}, "@seq": "3", "ce:initials": "V.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Sriuranpong", "@auid": "6603599644", "author-url": "https://api.elsevier.com/content/author/author_id/6603599644", "ce:indexed-name": "Sriuranpong V."}, {"ce:given-name": "Nutthada", "preferred-name": {"ce:given-name": "Nutthada", "ce:initials": "N.", "ce:surname": "Areepium", "ce:indexed-name": "Areepium N."}, "@seq": "4", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "117369800", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117369800"}, "ce:surname": "Areepium", "@auid": "13610558100", "author-url": "https://api.elsevier.com/content/author/author_id/13610558100", "ce:indexed-name": "Areepium N."}]}}}